The Spectris AD headset produces flashing lights and sounds designed to induce gamma waves in the brain. Credit: Cognito Therapeutics
A device that uses flickering lights and rhythmic sounds to stimulate gamma waves in the brain did not slow memory loss in people with Alzheimer’s disease, according to results from a long-awaited clinical trial. After 12 months, participants who used Cognito Therapeutics’ Spectris AD headset showed no improvement in cognitive function compared with those who received a sham device, although the company reported a possible benefit among people with mild cognitive impairment.
The findings were presented by Cognito Therapeutics, based in Cambridge, Massachusetts, at the Alzheimer’s Disease Clinical Trials Conference in Boston, Massachusetts, on November 16. The Spectris AD system consists of goggles and headphones that patients use at home for one hour a day. Its flashing lights and rhythmic clicks are designed to trigger gamma waves, brain activity associated with attention and memory.
In the trial, 673 people with Alzheimer’s disease were randomly assigned to use either an active or sham Spectris AD device for 60 minutes daily over 12 months. On a 156-point scale measuring cognition and the ability to perform everyday activities, participants using the active device declined by an average of 8.97 points. Those using the sham device declined by 8.82 points.
Cognito chief executive Christian Howell said he was disappointed by the overall results but maintained that the device appeared more effective in people with mild rather than moderate cognitive impairment. In the mild-impairment group, participants using the active device declined 41.6% more slowly than those using the sham device, with an average difference of 3 points.
“The effects we observed in the mild subgroup were very meaningful,” Howell said. “It gives me a sense of optimism moving forward.” He said the company plans to apply for approval from the U.S. Food and Drug Administration next year.
Can flashing lights slow Alzheimer’s disease? What the science shows
Researchers remain cautious
Independent researchers said the overall result did not support the device’s effectiveness. “The test was negative,” said Eric McDade, a neurologist at Washington University School of Medicine in St. Louis who was not involved in the study. “If anything were to happen after this, it would be a follow-up study in that milder population.”
Rob Howard, a psychiatrist and dementia expert at University College London, said the findings in the mild-impairment group were exploratory rather than convincing evidence of efficacy.
“If this were a drug, a clear failure like this would mean the company would not move forward with seeking regulatory approval,” Howard said. The device’s safety does not make it more useful to patients, he added.
Howard also noted that previous trials of Spectris AD had been unsuccessful. A small 2024 trial failed to show that the device slowed declines in cognitive and functional abilities among people with Alzheimer’s disease.1
A setback for gamma-wave research
The results are a setback for researchers investigating whether modulating gamma waves in the brain can improve brain health. The trial’s findings leave the potential benefit for people with mild cognitive impairment uncertain and in need of further study.
Source: www.nature.com


